-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster II

Molecular Pharmacology and Drug Resistance in Myeloid Diseases Program: Oral and Poster Abstracts
Type: Poster
Sunday, December 6, 2015: 6:00 PM-8:00 PM
Hall A, Level 2 (Orange County Convention Center)

Samantha L Savage1*, Christopher A. Eide2,3*, Kyle F Concannon1,3*, Daniel Bottomly, MS4*, Beth Wilmot, PhD4*, Shannon K. McWeeney, PhD4*, Julia Elizabeth Maxson, PhD5, Jeffrey W. Tyner, PhD6, Cristina E. Tognon, PhD1,3* and Brian J. Druker, MD1,3

1Knight Cancer Institute, Oregon Health and Science University, Portland, OR
2Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR
3Howard Hughes Medical Institute, Portland, OR
4Department of Bioinformatics and Computational Biology, Oregon Health & Science University, Portland, OR
5Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
6Knight Cancer Institute, Oregon Health & Science University, Portland, OR

Mika Kontro, MD1*, Samuli Eldfors, MSc2*, Muntasir Mamun Majumder, MSc, MPharm2*, Alun Parsons, MSc2*, Tea Pemovska, MSc2*, Olli Kallioniemi, MD, PhD2*, Krister Wennerberg, PhD2*, Caroline A Heckman, PhD2 and Kimmo Porkka, MD, PhD1

1Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
2Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland

Monika Jaruskova1,2*, Rajna Hercog3*, Nikola Curik1,4*, Vladimir Benes3*, Hana Klamova1,2* and Katerina Machova Polakova1,2*

1Institute of Hematology and Blood Transfusion, Prague, Czech Republic
2Institute of Clinical and Experimental Hematology, First Faculty of Medicine, Charles University, Prague, Czech Republic
3Genomics Core Facility, Heidelberg, Germany
4Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic

Chun Zhou, PhD1*, Daniela Di Marcantonio, PhD1, Esteban Martinez1*, Nehal Solanki-Patel1*, Suraj Peri, PhD1*, Claudia Scholl2, Stefan Fröhling2, David L. Wiest, PhD1 and Stephen Matthew Sykes, PhD1

1Fox Chase Cancer Center, Philadelphia, PA
2National Center for Tumor Diseases, Heidelberg, Germany

Jacqueline Martinez, MS1*, Nathalie Javidi-Sharifi1*, Isabel English1*, Shelton A. Viola, MD2*, Danielle Jorgens, PhD3*, Brian J. Druker, MD4,5 and Elie Traer, MD, PhD5

1Knight Cancer Institute, Oregon Health & Science University, Portland, OR
2Oregon Health & Sciences University, Portland, OR
3Oregon Health & Science University, Portland, OR
4Howard Hughes Medical Institute, Portland, OR
5Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR

Linda Resar, M.D.1, Stuart A Rushworth, PhD, BSc2*, Lingling Xian, MD, PhD3* and Kristian Bowles, MB BS, PhD, FRCP, FRCPath4*

1Department of Medicine; Division of Hematology, Department of Oncology, Institute of Cellular Engineering, Johns Hopkins University SOM, Baltimore, MD
2Norwich Medical School, University of East Anglia, Norwich, United Kingdom
3Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD
4Division of Hematology, University of East Anglia, Norwich, United Kingdom

Irum Khan, MD1, Maryam Zia, M.D.2, Marianna Halasi, Ph.D.3*, Peter Gann, M.D., ScD4*, Sujata Gaitonde, MD, FACP5* and Andrei Gartel, Ph.D.6*

1Division of Hematology/Oncology, University of Illinois at Chicago, Chicago, IL
2Division of Hematology/Oncology, University of Illinois College of Medicine At Chicago, Chicago, IL
3Division of Gastroenterology and Hepatology, University of Illinois-Chicago, Chicago
4Division of Pathology Research, University of Illinois-Chicago Hospital and Health Sciences System, Chicago
5Department of Pathology, University of Illinois at Chicago, Chicago
6Division of Gastroenterology and Hepatology, University of Illinois-Chicago Hospital and Health Sciences Center, Chicago, IL

Haijiao Zhang, MD1*, Kevin Matthew Watanabe-Smith, BS2*, Daniel Bottomly, MS3*, Beth Wilmot, PhD3*, Shannon K. McWeeney, PhD3*, Hagop M. Kantarjian, MD4, Judy Ho5*, Jeremy Davis5*, Blake Pond, MS6*, Gautam Borthakur, MD4, Abhijit Ramachandran, MS7*, Jorge E. Cortes4, Robert Collins, MD8 and Jeffrey W. Tyner, PhD9

1Oregon Health & Science University Knight Cancer Institute, Portland, OR
2Oregon Health and Science University, Portland, OR
3Department of Bioinformatics and Computational Biology, Oregon Health & Science University, Portland, OR
4Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
5AROG Pharmaceuticals, Dallas, TX
6Clinical Research Manager, University of Texas Southwestern Medical Center, Dallas, TX
7Clinical Operations, AROG Pharmaceuticals, Dallas, TX
8University of Texas Southwestern Medical Center, Dallas, TX
9Knight Cancer Institute, Oregon Health & Science University, Portland, OR

Jianyun Zhao1*, Xiaojia Niu1*, Holly Edwards2*, Yue Wang3*, Jeffrey W Taub, MD4, Hai Lin3* and Yubin Ge, PhD5

1Jilin University, Changchun, China
2Wayne State University, Detroit, MI
3The First Hospital of Jilin University, Changchun, China
4Department of Pediatric Hematology/Oncology, Children's Hospital of Michigan, Detroit, MI
5Department of Oncology, Karmanos Cancer Institute, Detroit, MI

Marisa J Hornbaker, B.S., Mary E Irwin, Ph.D.*, LaNisha Patterson, B.S.*, Shelley M Herbrich, MS*, Patrick Zweidler-McKay, MD, PhD and Joya Chandra, Ph.D.

Department of Pediatrics Research, The University of Texas M D Anderson Cancer Center, Houston, TX

Shaneice Mitchell, BS1,2*, Shelley Orwick, BS1*, Matthew Cannon, BS1*, Virginia M. Goettl, DVM , PhD1*, Taylor D. LaFollette1*, Erkan Baloglu, PhD3*, William Senapedis, PhD3*, Alison R. Walker, MD1, Bhavana Bhatnagar1*, Alice S. Mims, MD1, Rebecca B. Klisovic, MD1, Sumithira Vasu, MBBS4, William Blum, MD1, David M. Lucas, PhD1, James S. Blachly, MD1, Ramiro Garzon, MD4, Clara D. Bloomfield, MD4, Rosa Lapalombella, PhD1 and John C. Byrd, MD1,5

1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
2Biomedical Science Graduate Program, The Ohio State University, Columbus, OH
3Karyopharm Therapeutics, Inc, Newton, MA
4Comprehensive Cancer Center, The Ohio State University, Columbus, OH
5Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH

Oscar Lindblad1,2,3*, Eugenio Cordero1*, Alexandre Puissant4*, Lucy Macaulay1,2*, Nuzhat N. Kabir5*, Jianmin Sun1,2*, Karin Haraldsson6*, Åke Borg6*, Fredrik Levander7*, Kimberly Stegmaier, MD8, Kristian Pietras1*, Lars Ronnstrand1,2 and Julhash U. Kazi1,2,5*

1Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Medicon Village 404, Lund, Sweden
2Lund Stem Cell Center, Department of Laboratory Medicine, Lund University, Lund, Sweden
3Department of Hematology and Vascular Disorders, Skåne University Hospital, Lund, Sweden
4Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA
5Laboratory of Computational Biochemistry, KN Biomedical Research Institute, Barisal, Bangladesh
6Department of Oncology and Pathology, Lund University, Medicon Village 404, Lund, Sweden
7Bioinformatics Infrastructure for Life Sciences (BILS), Department of Immunotechnology, Lund University, Medicon Village 406, Lund, Sweden
8Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA

Myrna Rita Nahas, MD1*, Dina Stroopinsky, PhD1*, Hasan Rajabi, PhD2*, Ashujit Tagde, PhD2*, Athalia Rachel Pyzer, MD1*, Salvia Jain, MD3, Maxwell Douglas Coll1*, Michal Bar-Natan, MD1*, Rebecca Karp, MD1, Katarina Luptakova, MD1, Kristen Anna Palmer1*, Poorvi Somaiya1*, Jon Arnason, MD1, Malgorzata McMasters, MD1*, Robin Joyce, MD1, James D. Levine, MD1, Donald Kufe, MD2*, David E. Avigan, MD1 and Jacalyn Rosenblatt1

1Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
2Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
3Malignant Hematology and Bone Marrow Transplantation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Kelly J Norsworthy, MD1, Daniela Hernandez, MD1*, Meng Su, BS1, Megan E McCray, BA1*, Christopher A Esteb, BS1*, Roshantha A Chandraratna, PhD2*, B. Douglas Smith, MD1, Richard J Jones, MD1 and Gabriel Ghiaur, MD, PhD1

1Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
2Io Therapeutics, Inc., Santa Ana, CA

Sinto Sebastian Chirackal, PhD1*, Yuan Xiao Zhu, PhD2*, Esteban Braggio, PhD3*, Chang-Xin Shi, Ph.D.4*, Sonali Panchabhai, MBBS5*, Gregory Ahmann, BS6, Scott A. Van Wier, BS7*, Marta Chesi, PhD5, Leif Bergsagel, MD, PhD8, Keith Stewart, MD9 and Rafael Fonseca, MD7

1Haematology and Oncology, Mayo Clinic, Scottsale, AZ
2Research, Mayo Clinic, Scottsdale, AZ
3Department of Medicine, Mayo Clinic, Scottsdale, AZ
4Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ
5Mayo Clinic, Scottsdale, AZ
6Division of Hematology - Oncology, Mayo Clinic, Scottsdale, AZ
7Mayo Clinic, Scottsdale
8Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ
9Mayo Clinic Arizona, Scottsdale, AZ

*signifies non-member of ASH